| Harry Joseph Wallus, DO | |
|
333 Borthwick Ave, Portsmouth, NH 03801-7128 | |
| (603) 433-4012 | |
| (603) 433-5184 |
| Full Name | Harry Joseph Wallus |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 333 Borthwick Ave, Portsmouth, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215183751 | NPI | - | NPPES |
| 03351484 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 260578 (New York) | Secondary |
| 207P00000X | Emergency Medicine | T0638 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Harry Joseph Wallus, DO 74 Pleasant St, Ste 204, New London, NH 03257-5881 Ph: (603) 926-0088 | Harry Joseph Wallus, DO 333 Borthwick Ave, Portsmouth, NH 03801-7128 Ph: (603) 433-4012 |
News Archive
The human papillomavirus (HPV) may be to blame for the alarming increase of young adults with oropharyngeal cancer, according to researchers from Henry Ford Hospital in Detroit.
We live in fear of 'superbugs': infectious bacteria that don't respond to treatment by antibiotics, and can turn a routine hospital stay into a nightmare. A 2015 Health Canada report estimates that superbugs have already cost Canadians $1 billion, and are a "serious and growing issue." Each year two million people in the U.S. contract antibiotic-resistant infections, and at least 23,000 people die as a direct result.
Immune Pharmaceuticals Inc. announced today that its common stock has been approved for trading on NASDAQ OMX First North Premier, Stockholm ("First North").
Reality television programmes which focus on extreme weight loss and drastic changes to a person's appearance may be behind a dramatic increase in cosmetic and weight reduction surgery, according to University of Auckland researchers.
VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin (PLD) for the treatment of women with ovarian cancer whose disease has progressed on or recurred after platinum-based chemotherapy.
› Verified 1 days ago
Samuel W Trotzky, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 333 Borthwick Ave, Portsmouth, NH 03801 Phone: 603-433-4012 Fax: 603-433-5184 | |
Steven J Bos, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 333 Borthwick Ave, Portsmouth, NH 03801 Phone: 603-433-4012 Fax: 603-433-5184 | |
Samantha Arnold, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 333 Borthwick Ave, Portsmouth, NH 03801 Phone: 603-674-9496 | |
Dr. William P Carter Iii, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 333 Borthwick Ave, Portsmouth, NH 03801 Phone: 603-436-5110 | |
Alexandra Loomis, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 333 Borthwick Ave Ste 100, Portsmouth, NH 03801 Phone: 617-763-1295 | |
Dr. Brian Christopher Collins, D.O. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 73 Corporate Dr, Suite 100, Portsmouth, NH 03801 Phone: 603-610-8051 |